文献速递骨显像与常规 SPECT放射性药物与辐射防护

定量Na[18F]F PET/CT监测良性代谢性骨病治疗反应的系统评价

Diagnostic accuracy and clinical value of quantitative Na[18F]F PET/CT parameters to monitor therapeutic response in patients with benign metabolic bone diseases: A systematic review.
PubMed 文献 · Semin Nucl Med · 2026-10-28

该系统评价纳入13项研究共358例患者,聚焦CKD-MBD与FD/MAS,评估定量Na[18F]F PET/CT监测治疗反应的表现。PET动力学与体积学指标与骨形成率及循环标志物强相关,Ki与SUVR鉴别骨转换状态AUC可达0.98,优于PTH;但重建方案缺乏EARL统一标准,证据多来自小样本未校正队列。

要点

  • 定量Na[18F]F PET/CT对良性代谢性骨病区域骨转换与治疗反应具有高诊断准确性。
  • 地诺单抗治疗FD/MAS中,中剂量与高剂量组病灶总代谢活性降幅相当(-64.9% vs -67.0%)。
  • 仅1项研究明确提及EARL扫描仪认证,无研究记录符合EARL标准1或2。

核心结论

  • 定量Na[18F]F PET/CT对良性代谢性骨病区域骨转换与治疗反应监测具有高诊断准确性,但临床推广受限于缺乏统一的EARL合规协议、结局指标未标准化及小样本未校正队列。

研究设计与样本

  • 本系统评价前瞻性注册于PROSPERO(CRD420261413536),遵循PRISMA 2020指南,检索电子数据库纳入使用定量Na[18F]F PET/CT的代谢性骨病临床研究。
  • 共纳入13项研究,每项n=14-72例患者,合计358例,其中CKD-MBD 9项、FD/MAS 4项。
  • 偏倚风险采用QUADAS-2、ROBINS-I和QUIPS评估,结果以叙述性方式综合。

主要发现

  • 两项纵向研究评估治疗反应:FD/MAS中地诺单抗中剂量与高剂量组病灶总代谢活性降幅相当(-64.9% vs -67.0%)。
  • CKD-MBD中转换导向治疗显著降低骨动力学通量(Ki)。
  • PET动力学指标(Ki、FUR)与体积学指标(TV、TA、TLF)与骨形成率及循环生物标志物强相关。
  • Ki与背景校正摄取值比(SUVR)鉴别骨转换状态准确性高(ROC AUC最高达0.98),在CKD-MBD中优于血清甲状旁腺激素。
  • 重建参数报告差异大,仅1项研究明确提及EARL扫描仪认证,无研究记录符合EARL标准1或2。

关键数值与推荐

  • FD/MAS中地诺单抗中剂量与高剂量组病灶总代谢活性降幅分别为-64.9%与-67.0%。
  • Ki与SUVR鉴别骨转换状态的ROC AUC最高达0.98。
  • 纳入研究每项样本量为14-72例,合计358例。

临床怎么用

  • 可将定量Na[18F]F PET/CT的Ki与SUVR用于评估CKD-MBD骨转换状态,其鉴别准确性优于血清PTH。
  • 纵向监测FD/MAS地诺单抗治疗反应时,中剂量与高剂量组病灶代谢活性降幅相似,可供剂量选择参考。
  • 临床解读数值前需注意各研究重建方案不统一,缺乏EARL合规协议,跨中心比较需谨慎。

局限性

  • 多数文献为横断面与观察性队列,仅两项纵向研究评估治疗反应。
  • 纳入队列样本量小(每项14-72例),存在失访与未校正混杂,偏倚风险主要由此驱动。
  • 重建参数报告高度变异,仅1项研究提及EARL认证,无研究记录符合EARL标准1或2。
  • 结局指标未标准化,限制定量参数的横向可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Na[¹⁸F]F PET/CT is increasingly used to evaluate treatment responses in metabolic bone diseases (MBDs), where conventional serum biomarkers and structural imaging fail to show local dynamic changes. The performance and utility of Na[¹⁸F]F PET/CT in these diseases, however, has not been fully explored. We systematically evaluated the contemporary use of quantitative Na[¹⁸F]F PET/CT for measuring MBD treatment responses. METHODS: Current review was prospectively registered on PROSPERO (CRD420261413536) and follows PRISMA 2020 guidelines. Electronic databases were searched for clinical studies using quantitative Na[¹⁸F]F PET/CT in MBDs. Risk of bias was assessed via QUADAS-2, ROBINS-I and QUIPS. Results were synthesized narratively. RESULTS: Thirteen studies (n=14-72 patients; 358 total cases) met inclusion criteria, focusing on chronic kidney disease-mineral and bone disorder (CKD-MBD, n=9 studies) and fibrous dysplasia/McCune-Albright syndrome (FD/MAS, n=4 studies). Two longitudinal studies evaluated therapeutic response: denosumab in FD/MAS yielded comparable reductions in total lesion metabolic activity across moderate (-64.9%) and high doses (-67.0%), while turnover-guided therapy in CKD-MBD significantly reduced bone kinetic flux (Ki). Remaining literature comprised cross-sectional and observational cohorts. Here, PET kinetic (Ki, FUR) and volumetric metrics (TV, TA, TLF) correlated strongly with bone formation rates and circulating biomarkers. Ki and background-adjusted uptake ratios (SUVR) discriminated bone turnover states with high accuracy (ROC AUC up to 0.98), outperforming serum parathyroid hormone in CKD-MBD. Reporting of reconstruction settings was highly variable; only one study explicitly noted EARL scanner accreditation and none documented compliance with EARL Standard 1 or 2. Risk of bias was primarily driven by small cohort sizes, attrition and unadjusted confounding. CONCLUSIONS: Quantitative Na[¹⁸F]F PET/CT provides high diagnostic accuracy for tracking regional turnover and treatment response in benign MBDs. However, clinical adoption is hindered by a lack of harmonized EARL-compliant protocols, unstandardized outcome metrics and a reliance on small, unadjusted cohorts.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. van Schaik L, Huisman SA, Appelman-Dijkstra NM, et al. Diagnostic accuracy and clinical value of quantitative Na[18F]F PET/CT parameters to monitor therapeutic response in patients with benign metabolic bone diseases: A systematic review. Semin Nucl Med. 2026. PMID: 42951720. doi:10.1053/j.semnuclmed.2026.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。